Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A bile acid derivative with antibacterial activity and its pharmaceutical composition

A compound, drug technology, applied in the field of medicine

Active Publication Date: 2021-02-02
CHENGDU BIOBEL BIOTECHNOLOGY CO LTD
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

It has been reported that cholic acid compounds or derivatives chemically modified on the basis of their structures have more biological activities. Ursodeoxycholic acid is an endogenous cholic acid compound that has been approved for marketing in the treatment of cholestatic liver cirrhosis; other bile acids Acid derivatives have been reported to have the activity of inhibiting the germination of Clostridium difficile spores, such as the compound CamSA (systematic name: 3-[(3α,7α,12α-trihydroxy -24-oxo-5β-cholan-24-yl)amino]benzenesulfonic acid) and compound 12a reported in J.Med.Chem.2018,61,6759-6778 (systematic name: N-(Phenyl)-3α, 7α,12α-trihydroxy-5β-cholan-24-amide), but so far no bile acid derivatives that have the effect of inhibiting Clostridium difficile have been reported

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A bile acid derivative with antibacterial activity and its pharmaceutical composition
  • A bile acid derivative with antibacterial activity and its pharmaceutical composition
  • A bile acid derivative with antibacterial activity and its pharmaceutical composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0075] Embodiment 1: the synthesis of compound 1-1:

[0076]

[0077] Add 1 g of nor-CDCA, 15 ml of DMF (N,N-dimethylformamide), 0.86 g of TBTU (benzotriazole tetramethyltetrafluoroboric acid), 1 g of DIPEA (N, N-diisopropylethylamine) and 0.35 g of 2-amino-5-nitrothiazole, stirred at room temperature for 5-6 hours, TLC monitored the reaction progress until the nor-CDCA reaction was complete, added 50 ml of water and 50 ml of ethyl acetate , after stirring, stand still, separate the organic phase, extract the aqueous phase with ethyl acetate twice and combine, the organic phase is washed successively with 10 ml of 2% dilute hydrochloric acid, 1% potassium carbonate aqueous solution, and saturated brine, dried, and concentrated in vacuo. The residue was subjected to silica gel column chromatography and washed with petroleum ether / ethyl acetate system to obtain 0.8 g of a light yellow solid.

[0078] 1 HNMR (400MHz, CDCl 3 )δppm:8.33(s,1H),3.90(s,1H),3.61-3.46(m,2H), 2.71(...

Embodiment 2

[0080] Embodiment 2: the synthesis of compound 1-2:

[0081]

[0082] The raw materials were changed and synthesized by the same method as in Example 1.

[0083] 1 HNMR (400MHz, CD 3 OD) δppm: 8.40(s, 1H), 4.01-3.95(m, 1H), 3.82(q, J=3.0Hz, 1H), 3.46-3.33(m, 1H), 2.61(ddd, J=14.6, 9.9 ,4.7Hz,1H),2.48(ddd, J=15.1,8.8,6.4Hz,1H),2.38-2.23(m,2H),2.09-1.74(m,8H),1.73-1.30(m,7H), 1.26(t,J=7.1Hz,1H),1.22-0.95(m,2H),1.08(d,J=5.8Hz,3H),0.94(s,3H), 0.74(s,3H);

[0084] ESI-MS m / z:534.01[M-1] - .

Embodiment 3

[0085] Embodiment 3: the synthesis of compound 1-3:

[0086]

[0087] The raw materials were changed and synthesized by the same method as in Example 1.

[0088] 1 HNMR (400MHz, CD 3 OD) δppm: 8.39(s, 1H), 3.82(q, J=2.8Hz, 1H), 3.46-3.34(m, 1H), 2.60(ddd, J=15.0, 9.8, 5.1Hz, 1H), 2.47( ddd,J=15.3,9.3,6.6Hz,1H),2.29(d,J=11.5Hz,1H),2.08-1.94(m,3H),1.92-1.81(m,3H), 1.73-1.37(m, 8H), 1.37-1.09(m, 4H), 1.02(d, J=6.4Hz, 3H), 1.05-1.96(m, 1H), 0.90(s, 3H), 0.72(s, 3H);

[0089] ESI-MS m / z:518.01[M-1] - .

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides the compound represented by formula (I), or its stereoisomer, or its salt, or its solvate, or its prodrug, or its metabolite. This type of compound can effectively inhibit the growth of Clostridium difficile bacteria, and has significant antibacterial activity. It has a very good application prospect in the medicine of disease complications.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to a cholestane derivative with antibacterial activity and a medicinal composition thereof. Background technique [0002] Clostridium difficile (Clostridium difficile) is an obligate anaerobic bacterium of the genus Clostridium, which is very sensitive to oxygen and difficult to isolate and culture, hence the name, and generally parasitizes in the human intestinal tract. Usually Clostridium difficile infection is caused by excessive use of certain antibiotics, which breaks the balance of intestinal flora, makes the growth of Clostridium difficile flora accelerate, and causes inflammation. Clostridium difficile produces exotoxins A and B with different effects at different times. Toxin A is an enterotoxin, which first binds to mucosal cells in the early stage, causing primary damage, leading to inflammation of the intestinal wall, cell infiltration, increased permeabili...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07J43/00A61P31/04A61P1/00A61K31/58
CPCA61P1/00A61P31/04C07J43/003
Inventor 广兵阳泰董韧涵刘进覃传军黄胜谢建赖永新彭向阳许庆占伟彭坚王晓辉
Owner CHENGDU BIOBEL BIOTECHNOLOGY CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com